文献速递银屑病与炎症性皮肤病

富马酸酯治疗10-17岁中重度斑块状银屑病的随机双盲安慰剂对照试验

Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial.
PubMed 文献 · Br J Dermatol · 2021-02-22

这项多中心、随机、双盲、安慰剂对照IIIb期研究纳入10-17岁需系统治疗的中重度斑块状银屑病患者,按2:1随机接受富马酸酯(FAE,n=91)或安慰剂(n=43)治疗20周。FAE疗效优于安慰剂且差异有统计学和临床意义,药物相关不良事件更常见(76% vs 47%),以胃肠道紊乱最多见。

要点

  • FAE治疗20周PASI 75达55%,显著优于安慰剂19%。
  • PGA 0/1应答FAE组42%,安慰剂组7%,差异显著。
  • 药物相关不良事件FAE组76%,安慰剂组47%,以胃肠道反应最常见。

核心结论

  • FAE治疗20周对10-17岁中重度斑块状银屑病的疗效优于安慰剂,差异有统计学和临床意义。
  • FAE应用至40周总体耐受性良好,但仍需进一步研究。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照IIIb期研究,10-17岁需系统治疗的中重度斑块状银屑病患者按2:1随机接受FAE(n=91)或安慰剂(n=43)治疗20周,随后开放标签FAE治疗期。

主要发现

  • 双盲期药物相关不良事件FAE组76%,安慰剂组47%,胃肠道紊乱最常见。

关键数值与推荐

  • 共同主要终点为第20周PASI 75和PGA评分0或1(清除或几乎清除)。
  • FAE组PASI 75为55%,PGA 0/1为42%;安慰剂组分别为19%和7%。

临床怎么用

  • 对于10-17岁中重度斑块状银屑病需系统治疗的患者,FAE可作为考虑选项之一。
  • 治疗中需关注胃肠道不良事件,FAE组药物相关不良事件发生率高于安慰剂。

局限性

  • 研究仅覆盖20周双盲期,长期疗效和安全性需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Apart from biologics, no systemic drugs are approved in Europe for children with moderate-to-severe psoriasis. Retrospective observational studies have shown promising results for fumaric acid esters (FAE) in this setting. OBJECTIVES: To show superiority of FAE over placebo in terms of treatment response after 20 weeks in children and adolescents aged 10-17 years. METHODS: In a multicentre, randomized, double-blind, placebo-controlled phase IIIb study, patients aged 10-17 years with moderate-to-severe plaque psoriasis requiring systemic therapy were randomized 2 : 1 to receive FAE (n = 91) or placebo (n = 43) over 20 weeks, followed by an open-label FAE treatment phase. The coprimary endpoints were ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) and Physician's Global Assessment (PGA) score of 0 or 1 (clear or almost clear) at week 20. The study was registered with EudraCT number 2012-000035-82. RESULTS: At week 20, 55% [95% confidence interval (CI) 0·44-0·65] of FAE-treated patients achieved a PASI 75 response vs. 19% (95% CI 0·08-0·33) in the placebo group (absolute difference 36%, 95% CI 0·20-0·53; P < 0·001). In total, 42% (95% CI 0·32-0·53) in the FAE group vs. 7% (95% CI 0·01-0·19) in the placebo group achieved a PGA score of 0 or 1 at week 20 (absolute difference 35%, 95% CI 0·21-0·49; P < 0·001). During the double-blind period, drug-related adverse events occurred more frequently in patients receiving FAE compared with placebo (76% vs. 47%). Gastrointestinal disorders were the most common adverse events. CONCLUSIONS: FAE administered over a period of 20 weeks demonstrated a better response than placebo; the difference was statistically significant and clinically meaningful. Application up to 40 weeks was generally well tolerated. However, further studies are required.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hamm H, Wilsmann-Theis D, Tsianakas A, et al. Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial. Br J Dermatol. 2021. PMID: 33332574. doi:10.1111/bjd.19747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。